Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsPreferred Shares IssuedProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Ekso Bionics Holdings (EKSO) EBIAT (2016 - 2026)

Ekso Bionics Holdings has reported EBIAT over the past 14 years, most recently at -$4.7 million for Q4 2025.

  • On a quarterly basis, EBIAT fell 36.95% to -$4.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$11.7 million, a 3.22% decrease, with the full-year FY2025 number at -$11.7 million, down 3.22% from a year prior.
  • EBIAT reached -$4.7 million in Q4 2025 per EKSO's latest filing, down from -$1.4 million in the prior quarter.
  • The five-year high for EBIAT was -$1.3 million in Q2 2021, with the low at -$4.7 million in Q4 2025.
  • The 5-year median for EBIAT is -$3.2 million (2022), against an average of -$3.2 million.
  • The largest YoY upside for EBIAT was 89.18% in 2021 against a maximum downside of 179.85% in 2021.
  • Tracing EKSO's EBIAT over 5 years: stood at -$2.9 million in 2021, then dropped by 11.0% to -$3.2 million in 2022, then decreased by 1.13% to -$3.2 million in 2023, then decreased by 6.19% to -$3.4 million in 2024, then crashed by 36.95% to -$4.7 million in 2025.
  • According to Business Quant data, EBIAT over the past three periods came in at -$4.7 million, -$1.4 million, and -$2.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.